SI2686347T1 - Protitelesa proti CD70 - Google Patents
Protitelesa proti CD70 Download PDFInfo
- Publication number
- SI2686347T1 SI2686347T1 SI201231335T SI201231335T SI2686347T1 SI 2686347 T1 SI2686347 T1 SI 2686347T1 SI 201231335 T SI201231335 T SI 201231335T SI 201231335 T SI201231335 T SI 201231335T SI 2686347 T1 SI2686347 T1 SI 2686347T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antibody
- binding fragment
- seq
- variable
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (13)
- Protitelesa proti CD70 Patentni zahtevki1. Protitelo ali njegov antigen vezavni fragment, ki se veže na humani CD70, kjer protitelo ali antigen vezavni fragment obsega vsaj eno težkoverižno variabilno domeno (VH), ki obsega variabilen težkoverižen CDR3, variabilen težkoverižen CDR2 in variabilen težkoverižen CDR1, in vsaj eno lahkoverižno variabilno domeno (VL), ki obsega variabilen lahkoverižen CDR3, variabilen lahkoverižen CDR2 in variabilen lahkoverižen CDR1, kjer variabilni težkoverižni CDR3 obsega ali sestoji iz SEQ ID NO: 50 (DAGYSNHVPIFDS); variabilni težkoverižni CDR2 obsega ali sestoji iz SEQ ID NO: 27 (DINNEGGTTYYADSVKG); variabilni težkoverižni CDR1 obsega ali sestoji iz SEQ ID NO: 11 (VYYMN); variabilni lahkoverižni CDR3 obsega ali sestoji iz SEQ ID NO: 160 (ALFISNPSVE); variabilni lahkoverižni CDR2 obsega ali sestoji iz SEQ ID NO: 119 (NTNTRHS); in variabilni lahkoverižni CDR1 obsega ali sestoji iz SEQ ID NO: 250 (GLKSGSVTSDNFPT).
- 2. Izolirano protitelo ali antigen vezavni fragment po zahtevku 1, ki obsega težkoverižno variabilno domeno (VH), ki obsega ali sestoji iz aminokislinske sekvence, prikazane kot SEQ ID NO: 223, ali aminokislinske sekvence, kije vsaj 90-, 95-, 97-, 98- ali 99-odstotno enaka le-tej, in lahkoverižno variabilno domeno (VL), ki obsega ali sestoji iz aminokislinske sekvence, prikazane kot SEQ ID NO: 241, ali aminokislinske sekvence, kije vsaj 90-, 95-, 97-, 98- ali 99-odstotno enaka le-tej.
- 3. Izolirano protitelo ali antigen vezavni fragment po zahtevku 2, ki obsega težkoverižno variabilno domeno (VH), ki obsega aminokislinsko sekvenco, prikazano kot SEQ ID NO: 223, ali sestoji iz nje, in lahkoverižno variabilno domeno (VL), ki obsega aminokislinsko sekvenco, prikazano kot SEQ ID NO: 241, ali sestoji iz nje.
- 4. Protitelo po katerem koli od prejšnjih zahtevkov, ki je himemo protitelo lama-human, kjer sta domeni VH in VL izvedeni iz lame in je ena ali več konstantih domen, izvedenih iz humanega imunoglobulina, in ki po izbiri obsega zgibno regijo, domeno CH2 in domeno CH3 humanega IgG, prednostno humanega IgGl.
- 5. Protitelo ali antigen vezavni fragment po katerem koli od prejšnjih zahtevkov, ki izkazuje eno ali več efektorskih funkcij, izbranih izmed protitelesno odvisne celično posredovane citotoksičnosti (ADCC), kjer protitelo ali antigen vezavni fragment po izbiri izkazuje povečano funkcijo ADCC v primerjavi z ekvivalentnim protitelesom, ki obsega naravno humano Fc-domeno, komplementno odvisne citotoksičnosti (CDC) in protitelesno odvisne celično posredovane fagocitoze (ADCP) proti celicam, ki eksprimirajo humani CD70 na celični površini, kot so CD70 eksprimirajoče rakave celice.
- 6. Protitelo po katerem koli od prejšnjih zahtevkov, ki je nefukoziliran IgG, prednostno nefukoziliran humani IgGl.
- 7. Izoliran polinukleotid, ki kodira protitelo ali antigen vezavni fragment po katerem koli od prejšnjih zahtevkov.
- 8. Ekspresijski vektor, ki obsega polinukleotid po zahtevku 7, funkcionalno vezan na regulatome sekvence, ki dopuščajo ekspresijo antigen vezavnega polipeptida v gostiteljski celici ali ekpresijskem sistemu brez celice.
- 9. Gostiteljska celica ali ekpresijski sistem brez celice, ki vsebuje ekspresijski vektor po zahtevku 8.
- 10. Postopek za izdelavo rekombinantnega protitelesa ali njegovega antigen vezavnega fragmenta, ki obsega kultiviranje gostiteljske celice ali ekpresijskega sistema brez celice po zahtevku 9 v razmerah, ki dopuščajo ekspresijo protitelesa ali antigen vezavnega fragmenta, in rekuperiranje eksprimiranega protitelesa ali antigen vezavnega fragmenta.
- 11. Farmacevtski sestavek, ki obsega protitelo ali antigen vezavni fragment po katerem koli od zahtevkov 1-6 in vsaj en farmacevtsko sprejemljiv nosilec ali ekscipient.
- 12. Protitelo ali antigen vezavni fragment po katerem koli od zahtevkov 1-6 za uporabo pri: (a) inhibiranju rasti CD70 eksprimirajočih tumorskih celic pri humanem pacientu; ali (b) zdravljenju ali preprečevanju raka pri humanem pacientu, kjer je rak po izbiri tisti, ki izkazuje ekspresijo CD70 z majhnim številom kopij.
- 13. Protitelo ali antigen vezavni fragment po katerem koli od zahtevkov 1-6 za uporabo pri zdravljenju ali preprečevanju raka pri humanem pacientu, kjer je rak izbran iz skupine, ki jo sestavljajo: velikocelični limfom B, kronična limfocitna levkemija, Burkittov limfom, Hodgkinov limfom, Nehodgkinov limfom, plaščnocelični limfom, pankreasni karcinom, kutani T-celični limfom, želodčni rak, pljučni rak, melanom, glioblastom in ovarijski rak.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161453390P | 2011-03-16 | 2011-03-16 | |
US201161503871P | 2011-07-01 | 2011-07-01 | |
EP12710486.7A EP2686347B1 (en) | 2011-03-16 | 2012-03-16 | Antibodies to cd70 |
PCT/EP2012/054733 WO2012123586A1 (en) | 2011-03-16 | 2012-03-16 | Antibodies to cd70 |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2686347T1 true SI2686347T1 (sl) | 2018-08-31 |
Family
ID=45878935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201231335T SI2686347T1 (sl) | 2011-03-16 | 2012-03-16 | Protitelesa proti CD70 |
Country Status (18)
Country | Link |
---|---|
US (6) | US9765148B2 (sl) |
EP (1) | EP2686347B1 (sl) |
JP (2) | JP5982409B2 (sl) |
CN (1) | CN103596979B (sl) |
AU (1) | AU2012228194B2 (sl) |
BR (1) | BR112013021562B1 (sl) |
CA (1) | CA2828753C (sl) |
CY (1) | CY1120471T1 (sl) |
DK (1) | DK2686347T3 (sl) |
ES (1) | ES2670874T3 (sl) |
HU (1) | HUE039849T2 (sl) |
IL (1) | IL228001B (sl) |
PL (1) | PL2686347T3 (sl) |
PT (1) | PT2686347T (sl) |
RU (1) | RU2604196C2 (sl) |
SI (1) | SI2686347T1 (sl) |
TR (1) | TR201807202T4 (sl) |
WO (1) | WO2012123586A1 (sl) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2723197C (en) | 2008-05-02 | 2017-09-19 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
RU2604196C2 (ru) | 2011-03-16 | 2016-12-10 | арДЖЕН-ИКС Н.В. | Антитела против cd70 |
WO2014089113A1 (en) * | 2012-12-03 | 2014-06-12 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
EP3457138A3 (en) * | 2013-04-30 | 2019-06-19 | Université de Montréal | Novel biomarkers for acute myeloid leukemia |
CA2921639A1 (en) * | 2013-09-05 | 2015-03-12 | Aduro Biotech Holdings, Europe B.V. | Cd70-binding peptides and method, process and use relating thereto |
US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
KR102390359B1 (ko) * | 2014-09-29 | 2022-04-22 | 삼성전자주식회사 | 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체 |
WO2017044752A1 (en) * | 2015-09-10 | 2017-03-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
BR112019023608A2 (pt) | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
GB2567613A (en) * | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
AU2018361957B2 (en) | 2017-10-31 | 2023-05-25 | Staten Biotechnology B.V. | Anti-ApoC3 antibodies and methods of use thereof |
GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
WO2019149743A1 (en) | 2018-01-30 | 2019-08-08 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
US11377500B2 (en) * | 2018-02-01 | 2022-07-05 | Pfizer Inc. | Antibodies specific for CD70 and their uses |
US11396551B2 (en) | 2018-02-01 | 2022-07-26 | Pfizer Inc. | Chimeric antigen receptors targeting CD70 |
CA3099364A1 (en) | 2018-05-11 | 2019-11-14 | Crispr Therapeutics Ag | Methods and compositions for treating cancer comprising engineered t cells comprising modified chimeric antigen receptors |
US20220047634A1 (en) * | 2018-11-30 | 2022-02-17 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptor factories and methods of use thereof |
TW202038958A (zh) | 2018-12-18 | 2020-11-01 | 比利時商阿根思公司 | Cd70組合治療 |
CA3138633A1 (en) | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
CN111909966B (zh) * | 2020-04-01 | 2021-09-21 | 苏州克睿基因生物科技有限公司 | 一种制备经修饰的免疫细胞的方法 |
TW202214697A (zh) | 2020-06-30 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗cd70抗體及其應用 |
US20230266332A1 (en) | 2020-07-28 | 2023-08-24 | Inserm (Institut National De La Santè Et De La Recherch Médicale) | Methods and compositions for preventing and treating a cancer |
US20230051406A1 (en) | 2020-11-13 | 2023-02-16 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
US20240024475A1 (en) | 2020-12-01 | 2024-01-25 | Cure Genetics Co., Ltd | Antigen-Binding Protein Targeting CD70 and Use Thereof |
CN114685657A (zh) * | 2020-12-31 | 2022-07-01 | 康诺亚生物医药科技(成都)有限公司 | 一种功能增强型抗体阻断剂的开发及其应用 |
WO2022253219A1 (en) * | 2021-05-31 | 2022-12-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric cd70 |
CN113292653B (zh) * | 2021-06-17 | 2022-11-11 | 南京蓝盾生物科技有限公司 | 具有增强的adcp效应的抗cd70抗体及其应用 |
CN113754769B (zh) | 2021-10-13 | 2023-06-06 | 宜明昂科生物医药技术(上海)股份有限公司 | 靶向cd70的抗体及其制备和用途 |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
DE19747418C1 (de) | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
US20030148321A1 (en) | 2001-08-24 | 2003-08-07 | Iris Pecker | Methods and kits for diagnosing and monitoring hematopoietic cancers |
US20070072178A1 (en) | 2001-11-05 | 2007-03-29 | Torsten Haferlach | Novel genetic markers for leukemias |
WO2003046581A2 (en) | 2001-11-27 | 2003-06-05 | Oxford Glycosciences (Uk) Ltd | Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers |
US7261892B2 (en) | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US8039218B2 (en) | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
ATE472338T1 (de) | 2003-02-20 | 2010-07-15 | Seattle Genetics Inc | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs |
US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
AU2004223837C1 (en) | 2003-03-24 | 2012-03-15 | Zymogenetics, Inc. | Anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
AU2005250499B2 (en) * | 2004-06-03 | 2011-12-08 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
US8337838B2 (en) | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
US7641903B2 (en) | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
AU2005295595C1 (en) | 2004-10-15 | 2012-06-21 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
WO2006047249A1 (en) | 2004-10-22 | 2006-05-04 | Zymogenetics, Inc. | Anti-il-22ra antibodies and binding partners and methods of using in inflammation |
CA2605507C (en) * | 2005-04-19 | 2016-06-28 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
EP1872124A4 (en) | 2005-04-19 | 2008-06-11 | Prediction Sciences Llc | DIAGNOSTIC MARKERS FOR THE TREATMENT AND EVOLUTION OF BREAST CANCER AND METHODS OF USE |
US20080280297A1 (en) | 2005-07-15 | 2008-11-13 | The Trustees Of Columbia University In The City Of | Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia |
CN101370830A (zh) * | 2005-09-26 | 2009-02-18 | 米德列斯公司 | 抗cd70的人单克隆抗体 |
EA016186B1 (ru) * | 2005-09-26 | 2012-03-30 | Медарекс, Инк. | Человеческие моноклональные антитела к cd70 и их применение |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
US20070237764A1 (en) * | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
RU2487888C2 (ru) | 2006-06-12 | 2013-07-20 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи | Одноцепочечные мультивалентные связывающие белки с эффекторной функцией |
EP2099823B2 (en) * | 2006-12-01 | 2022-02-09 | Seagen Inc. | Variant target binding agents and uses thereof |
WO2008074004A2 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
AR062123A1 (es) * | 2007-07-27 | 2008-10-15 | Inst Nac De Tecnologia Agropec | Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6 dominio dimerico, metodo de inmunodeteccion de rotavirus, composiciones, metodos de prevencion y tratamiento de infecciones con rotavirus |
KR100807069B1 (ko) | 2007-09-21 | 2008-02-25 | 고려대학교 산학협력단 | 암 치료용 의약 조성물 |
AU2008324203A1 (en) | 2007-11-05 | 2009-05-14 | Novartis Ag | Methods and compositions for measuring Wnt activation and for treating Wnt-related cancers |
BRPI0906903B8 (pt) * | 2008-04-11 | 2021-05-25 | Seattle Genetics Inc | anticorpo monoclonal e método de detecção da expressão de cd70 |
CA2725919A1 (en) | 2008-05-28 | 2009-12-03 | Roland Antonius Paulus Romijn | Method for the production of proteins or protein fragments |
GB2461546B (en) * | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
WO2010014948A1 (en) | 2008-08-01 | 2010-02-04 | The University Of Utah Research Foundation | Methods of treatment using wnt inhibitors |
US20110190157A1 (en) | 2008-08-15 | 2011-08-04 | The Regents Of The University Of California | Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia |
CN105079805A (zh) | 2008-09-26 | 2015-11-25 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
HUE042919T2 (hu) * | 2008-12-19 | 2019-07-29 | Ablynx Nv | Genetikai immunizáció sejthez kapcsolódó antigének - például P2X7, CXCR7 vagy CXCR4 - elleni immunglobulinok elõállítására |
ES2571235T3 (es) | 2009-04-10 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3 |
SI2464232T1 (sl) | 2009-08-10 | 2016-03-31 | Samumed, Llc. | Indazolovi inhibitorji signalne poti WNT in njihova terapevtska uporaba |
WO2011035433A1 (en) | 2009-09-23 | 2011-03-31 | University Health Network | Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers |
JP5818804B2 (ja) | 2009-11-19 | 2015-11-18 | メルク セローノ ソシエテ アノニム | ヒトil−22raに対するヒト化抗体 |
CA2785964C (en) | 2009-12-29 | 2021-03-30 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd27 antibody |
GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
PT2581113T (pt) | 2010-06-11 | 2018-07-04 | Univ Kyushu Nat Univ Corp | Anticorpo anti-tim-3 |
PL2665749T3 (pl) | 2011-01-19 | 2016-06-30 | Cantargia Ab | Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych |
RU2604196C2 (ru) | 2011-03-16 | 2016-12-10 | арДЖЕН-ИКС Н.В. | Антитела против cd70 |
WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
JO3625B1 (ar) | 2011-09-22 | 2020-08-27 | Amgen Inc | بروتينات رابطة للأنتيجين cd27l |
GB2504139B (en) * | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
WO2013093508A2 (en) | 2011-12-22 | 2013-06-27 | Oslo University Hospital Hf | Wnt pathway inhibitors |
JO3787B1 (ar) | 2012-03-15 | 2021-01-31 | Janssen Biotech Inc | أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها |
SG11201405919QA (en) | 2012-03-21 | 2014-10-30 | Erytech Pharma | Medicament for the treatment of acute myeloid leukemia (aml) |
WO2013177420A2 (en) | 2012-05-23 | 2013-11-28 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of bcr-abl positive lymphoblastic leukemias |
CA2875372C (en) | 2012-06-15 | 2019-04-09 | Curegenix Inc. | Compound as wnt signaling inhibitor, composition, and use thereof |
US20150203840A1 (en) | 2012-08-31 | 2015-07-23 | Argen-X N.V. | Method for producing antibody molecules having inter-species, intra-target cross-reactivity |
WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
WO2014100772A1 (en) | 2012-12-21 | 2014-06-26 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
WO2014126836A1 (en) | 2013-02-14 | 2014-08-21 | Bristol-Myers Squibb Company | Tubulysin compounds, methods of making and use |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
AU2015229448B2 (en) | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Cd70及cd3抗體構築體 |
EP3125645A1 (en) | 2015-07-31 | 2017-02-01 | Bleckmann GmbH & Co. KG | Flange assembly for securing a heating device to a fluid container |
WO2017044752A1 (en) | 2015-09-10 | 2017-03-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
WO2017079112A1 (en) | 2015-11-03 | 2017-05-11 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
US11027021B2 (en) | 2016-03-15 | 2021-06-08 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors |
GB2567613A (en) | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
-
2012
- 2012-03-16 RU RU2013146106/10A patent/RU2604196C2/ru active
- 2012-03-16 PT PT127104867T patent/PT2686347T/pt unknown
- 2012-03-16 US US14/005,113 patent/US9765148B2/en active Active
- 2012-03-16 EP EP12710486.7A patent/EP2686347B1/en active Active
- 2012-03-16 PL PL12710486T patent/PL2686347T3/pl unknown
- 2012-03-16 CA CA2828753A patent/CA2828753C/en active Active
- 2012-03-16 WO PCT/EP2012/054733 patent/WO2012123586A1/en active Application Filing
- 2012-03-16 HU HUE12710486A patent/HUE039849T2/hu unknown
- 2012-03-16 SI SI201231335T patent/SI2686347T1/sl unknown
- 2012-03-16 BR BR112013021562-3A patent/BR112013021562B1/pt active IP Right Grant
- 2012-03-16 DK DK12710486.7T patent/DK2686347T3/en active
- 2012-03-16 AU AU2012228194A patent/AU2012228194B2/en active Active
- 2012-03-16 TR TR2018/07202T patent/TR201807202T4/tr unknown
- 2012-03-16 ES ES12710486.7T patent/ES2670874T3/es active Active
- 2012-03-16 JP JP2013558466A patent/JP5982409B2/ja active Active
- 2012-03-16 CN CN201280013552.5A patent/CN103596979B/zh active Active
-
2013
- 2013-08-18 IL IL228001A patent/IL228001B/en active IP Right Grant
- 2013-11-06 US US14/073,462 patent/US8834882B2/en active Active
-
2014
- 2014-01-24 US US14/163,752 patent/US9765149B2/en active Active
-
2015
- 2015-02-19 US US14/626,038 patent/US11072665B2/en active Active
-
2016
- 2016-05-24 JP JP2016103443A patent/JP6261651B2/ja active Active
-
2018
- 2018-07-27 CY CY20181100783T patent/CY1120471T1/el unknown
-
2019
- 2019-02-18 US US16/278,522 patent/US11434298B2/en active Active
-
2022
- 2022-07-11 US US17/811,645 patent/US20230265201A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2686347T1 (sl) | Protitelesa proti CD70 | |
JP2013545455A5 (sl) | ||
JP2020508655A5 (sl) | ||
HRP20180147T1 (hr) | Cea protutijela | |
RU2018146050A (ru) | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген | |
IL259927B2 (en) | Humanized antibodies against cd73 | |
HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
JP2019525738A5 (sl) | ||
JP2018529327A5 (sl) | ||
RU2012142230A (ru) | Антитела против csf-1r человека и их применение | |
RU2010129045A (ru) | Связывающие молекулы к рецептору ох40 человека | |
JP2014039548A5 (sl) | ||
JP2010533498A5 (sl) | ||
IL262726B1 (en) | Antibodies that recognize tau | |
FI3401334T3 (fi) | Monoklonaalisia vasta-aineita Claudin-18:aa vastaan syövän hoitamiseksi | |
WO2010132659A3 (en) | Anti-human cd52 immunoglobulins | |
JP2012525829A5 (sl) | ||
JP2013545738A5 (sl) | ||
JP2017506067A5 (sl) | ||
RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
RU2014118555A (ru) | Химерные антигенные рецепторы к cd22 | |
RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII |